BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• BRAF V600E mutations occur in ~10% of colorectal cancers, associated with poor prognosis.
• Current targeted therapies for BRAF V600E colorectal cancer show limited and heterogeneous responses.
• Understanding the underlying biology of BRAF V600E colorectal cancer is crucial for developing effective treatments.

Purpose of the Study:

• To identify and characterize distinct molecular subgroups within BRAF V600E colorectal cancers.
• To investigate the biological pathways and molecular features associated with these subgroups.
• To provide insights for developing targeted therapeutic strategies for specific BRAF V600E colorectal cancer subtypes.

Main Methods:

• Utilized non-negative matrix factorization for unsupervised clustering on gene expression data from 218 BRAF V600E colorectal cancer patients.
• Performed pathway analysis to characterize identified subgroups.
• Validated findings using proteomics data.

Main Results:

• Identified two distinct BRAF V600E colorectal cancer subtypes, BM1 and BM2, independent of MSI status, PI3K mutation, gender, and sidedness.
• BM1 subtype is characterized by KRAS/AKT pathway activation, mTOR/4EBP deregulation, and epithelial-mesenchymal transition (EMT).
• BM2 subtype displays significant cell cycle deregulation, with high CDK1 and low cyclin D1 levels.

Conclusions:

• BRAF V600E colorectal cancer patients exhibit heterogeneous biology and should not be treated as a single group.
• Characterization of BM1 and BM2 subtypes reveals distinct molecular motifs exploitable for targeted drug development.
• Further research into these subtypes may lead to improved therapeutic outcomes for BRAF V600E colorectal cancer.